Citations

Showing 10 of 108104 citations.

Multicancer early detection: International summit to Clarify the Roadmap
Limburg, Paul J. , Ahlquist, David A. , Johnson, Sonali , Zürn, Shalini Jayasekar, Kisiel, John B. , Smith, Robert A. , Kisiel, John B , Limburg, Paul J

Mayo Clinic

Cancer | February 8, 2022 | Volume: 128 | Issue: S4 | Pages: 859-860

10.1002/cncr.33964 | PMID 35133657 Get It

To expedite the development and application of potentially transformative multicancer early detection assays, an international summit was hosted by the Mayo Clinic Cancer Center, the American Cancer Society, and the Union for International Cancer Control on World Cancer Day 2020 at the historic Mayowood Mansion in Rochester, Minnesota. Insights shared during this unique summit have been formulated into a series of expert‐authored commentaries, which accompany this introductory article.
Development and evaluation of safety and effectiveness of novel cancer screening tests for routine clinical use with applications to multicancer detection technologies
Doubeni, Chyke A. , Pennello, Gene , Carlson, Robert W. , Lau, Yan Kwan, Pennello, Gene A , Carlson, Robert W , Lau, Yan Kwan , Lin, Jennifer S , Doubeni, Chyke A.

Mayo Clinic

Cancer | February 8, 2022 | Volume: 128 | Issue: S4 | Pages: 883-891

10.1002/cncr.33954 | PMID 35133658 Get It

Multicancer screening is a promising approach to improving the detection of preclinical disease, but current technologies have limited ability to identify precursor or early stage lesions, and approaches for developing the evidentiary chain are unclear. Frameworks to enable development and evaluation from discovery through evidence of clinical effectiveness are discussed.
Multicancer early detection test: Preclinical, translational, and clinical evidence–generation plan and provocative questions
Kisiel, John B. , Papadopoulos, Nickolas , Liu, Minetta C. , Crosby, David L. , Srivastava, Sudhir , Hawk, Ernest T. , Kisiel, John B

Mayo Clinic

Cancer | February 8, 2022 | Volume: 128 | Issue: S4 | Pages: 861-874

10.1002/cncr.33912 | PMID 35133659 Get It

Minimally invasive molecular biomarkers have been applied to the early detection of multiple cancers in large scale case‐control and cohort studies. These demonstrations of feasibility herald the potential for permanent transformation of current cancer screening paradigms. This commentary discusses the major opportunities and challenges facing the preclinical development and clinical validation of multicancer early detection test strategies. From a diverse set of early detection research perspectives, the authors recommend specific approaches and highlight important questions for future investigation.
Comparative Effectiveness of Landmark-guided Greater Occipital Nerve (GON) Block at the Superior Nuchal Line Versus Ultrasound-guided GON Block at the Level of C2
Kissoon, Narayan R., O’Brien, Travis G., Bendel, Markus A., Eldrige, Jason S., Hagedorn, Jonathan M., Mauck, William D., Moeschler, Susan M., Olatoye, Oludare O., Pittelkow, Thomas P., Watson, James C., Pingree, Matthew J., Kissoon, Narayan R., O’Brien, Travis G., Bendel, Markus A., Eldrige, Jason S., Hagedorn, Jonathan M., Mauck, William D., Moeschler, Susan M., Olatoye, Oludare O., Pittelkow, Thomas P., Watson, James C., Pingree, Matthew J.

Mayo Clinic

The Clinical Journal of Pain | February 8, 2022 | Volume: 38 | Issue: 4 | Pages: 271-278

10.1097/ajp.0000000000001023 | PMID 35132029 Get It

Objectives: The purpose of this single center, prospective randomized controlled trial was to compare clinical outcomes between an ultrasound-guided greater occipital nerve block (GONB) at the C2 vertebral level versus landmark-based GONB at the superior nuchal line. Methods: Patients with occipital neuralgia or cervicogenic headache were randomized to receive either a landmark-based GONB with sham ultrasound at the superior nuchal line or ultrasound-guided GONB at the C2 vertebral level with blinding of patients and data analysis investigators. Clinical outcomes were assessed at 30 minutes, 2 weeks, and 4 weeks postinjection. Results: Thirty-two patients were recruited with 16 participants in each group. Despite randomization, the ultrasound-guided GONB group reported higher numeric rating scale (NRS) scores at baseline. Those in the ultrasound-guided GONB group had a significant decrease in NRS from baseline compared with the landmark-based GONB group at 30 minutes (change of NRS of 4.0 vs. 2.0) and 4-week time points (change of NRS of 2.5 vs. −0.5). Both groups were found to have significant decreases in Headache Impact Test-6. The ultrasound-guided GONB had significant improvements in NRS, severe headache days, and analgesic use at 4 weeks when compared with baseline. No serious adverse events occurred in either group. Conclusions: Ultrasound-guided GONBs may provide superior pain reduction at 4 weeks when compared with landmark-based GONBs for patients with occipital neuralgia or cervicogenic headache.
Adverse Events Associated With 10-kHz Dorsal Column Spinal Cord Stimulation
D’Souza, Ryan S. , Olatoye, Oludare, Butler, Casey S. , Ashmore, Zachary , Ashmore, Zachary M, D'Souza, Ryan S , Barman, Ross , Hagedorn, Jonathan M.

Mayo Clinic

The Clinical Journal of Pain | February 8, 2022 | Volume: 38 | Issue: 5 | Pages: 320-327

10.1097/ajp.0000000000001026 | PMID 35132023 Get It

Background: High-frequency (10-kHz) spinal cord stimulation (SCS) continues to be an emerging therapy in chronic pain management. The same complications that plagued earlier SCS systems may affect newer stimulation technologies, although there is limited data on the type of complications and surgical management of these complications. Objective: The aim of this study was to systematically examine real-world complications associated with 10-kHz SCS reported on the Manufacturer and User Facility Device Experience (MAUDE) database. Materials and Methods: The MAUDE database was queried for entries reported between January 1, 2016 and December 31, 2020. Entries were classified into procedural complications, device-related complications, patient complaints, surgically managed complications, serious adverse events, and/or other complications. Primary outcomes included type and frequency of complications, and surgical management of complications. Results: A total of 1651 entries were analyzed. Most entries were categorized as procedural complications (72.6%), followed by serious adverse events (10.5%), device-related complications (10.5%), and patient complaints (9.9%). Most complications were managed surgically with explant (50.9%) rather than revision (5.0%) or incision/drainage (6.6%). Of procedural complications, the most common entries included non-neuraxial infection (52.9%), new neurological symptoms (14.7%), and dural puncture (9.5%). Of device-related complications, the most common entries included lead damage (41.6%), erosion (18.5%), and difficult insertion (11.5%). Conclusion: This retrospective 5-year analysis of complications from10-kHz SCS provides a real-world assessment of safety data unique for this stimulation modality. This analysis may help inform future clinical decisions, lead to device enhancement and optimization, and improve mitigation of risks to provide safe and efficacious use of 10-kHz SCS.
The Case of the Red Extremities
Abarikwu, Kelechi, Komara, James, Urumov, Andrej, Komara, James S, Urumov, Andrej

Mayo Clinic

Clinical Practice and Cases in Emergency Medicine | February 8, 2022 | Volume: 6 | Issue: 1 | Pages: 95-96

10.5811/cpcem.2021.10.52891 | PMID 35226858 Get It

Case Presentation: A 37-year-old man with severe obstructive sleep apnea presented to the emergency department with burning pain, redness and swelling in his hands and feet, worsening for several weeks. Pertinent laboratory studies revealed polycythemia. Discussion: Erythromelalgia is a clinical diagnosis characterized by painful burning, erythema, warmth, and edema usually involving the distal extremities. Therapeutic goals are focused on symptom reduction, while also managing the underlying condition in cases of secondary erythromelalgia. Pharmacological and non-pharmacological therapies have proven to be of limited success.
Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies
Kanack, Adam J. , Singh, Bandana, George, Gemlyn , Gundabolu, Krishna , Koepsell, Scott A. , Moser, Karen , Smock, Kristi J. , Green, David , Major, Ajay , Ashrani, Aneel A. , Bayas, Antonios , Grill, Diane E. , Padmanabhan, Anand , Abou-Ismail, Mouhamed Yazan , Major, Ajay , Padmanabhan, Anand , Gundabolu, Krishna , Chan, Clarence W. , Wool, Geoffrey D. , Reding, Mark T.

Mayo Clinic

American Journal of Hematology | February 8, 2022 | Volume: 97 | Issue: 5 | Pages: 519-526

10.1002/ajh.26488 | PMID 35132672 Get It

AbstractRare cases of COVID‐19 vaccinated individuals develop anti‐platelet factor 4 (PF4) antibodies that cause thrombocytopenia and thrombotic complications, a syndrome referred to as vaccine‐induced immune thrombotic thrombocytopenia (VITT). Currently, information on the characteristics and persistence of anti‐PF4 antibodies that cause VITT after Ad26.COV2.S vaccination is limited, and available diagnostic assays fail to differentiate Ad26.COV2.S and ChAdOx1 nCoV‐19‐associated VITT from similar clinical disorders, namely heparin‐induced thrombocytopenia (HIT) and spontaneous HIT. Here we demonstrate that while Ad26.COV2.S‐associated VITT patients are uniformly strongly positive in PF4‐polyanion enzyme‐linked immunosorbent assays (ELISAs); they are frequently negative in the serotonin release assay (SRA). The PF4‐dependent p‐selectin expression assay (PEA) that uses platelets treated with PF4 rather than heparin consistently diagnosed Ad26.COV2.S‐associated VITT. Most Ad26.COV2.S‐associated VITT antibodies persisted for >5 months in PF4‐polyanion ELISAs, while the PEA became negative earlier. Two patients had otherwise unexplained mild persistent thrombocytopenia (140‐150 x 103/µL) 6 months after acute presentation. From an epidemiological perspective, differentiating VITT from spontaneous HIT, another entity that develops in the absence of proximate heparin exposure, and HIT is important, but currently available PF4‐polyanion ELISAs and functional assay are non‐specific and detect all three conditions. Here, we report that a novel un‐complexed PF4 ELISA specifically differentiates VITT, secondary to both Ad26.COV2.S and ChAdOx1 nCoV‐19, from both spontaneous HIT, HIT and commonly‐encountered HIT‐suspected patients who are PF4/polyanion ELISA‐positive but negative in functional assays. In summary, Ad26.COV2.S‐associated VITT antibodies are persistent, and the un‐complexed PF4 ELISA appears to be both sensitive and specific for VITT diagnosis.
Determinants of Vancomycin Trough Concentration in Patients Receiving Continuous Veno-Venous Hemodialysis
Quinn, Nicholas J. , Yerke, Jason , Srinivas, Pavithra , Hohlfelder, Benjamin , Sacha, Gretchen , Wanek, Matthew R, Hohlfelder, Benjamin , Wanek, Matthew

Mayo Clinic

Annals of Pharmacotherapy | February 8, 2022 | Volume: 56 | Issue: 10 | Pages: 1133-1138

10.1177/10600280211073370 | PMID 35130750 Get It

Background: Vancomycin pharmacokinetics are altered in the critically ill and are further distorted by renal replacement therapy. Limited literature is available evaluating vancomycin dosing in continuous veno-venous hemodialysis (CVVHD). Objective: The goal of this analysis was to identify factors that affect vancomycin trough concentration in patients on CVVHD and to determine an appropriate dosing strategy. Methods: This was a single-center, retrospective cohort study of adult inpatients admitted to the Cleveland Clinic from May 2016-December 2017. Patients in the intensive care unit who received ≥ 2 doses of vancomycin during CVVHD were included. Patients with interruptions of CVVHD inappropriately timed troughs, a change in dialysate rate, and those who received different vancomycin dosages were excluded. Multivariable linear regression including age, sex, weight, Sequential Organ Failure Assessment score, albumin, 24-hour urine output (UOP), dialysate rate, filter type, and vancomycin dose was run to determine predictors of vancomycin concentration. Results: A total of 160 patients were included. The median vancomycin dose was 12.6 mg/kg with a trough of 24.6 mcg/mL. Weight, 24-hour UOP, vancomycin dose (mg/kg), and dialysate rate (mL/kg/h) were all determined to be independent predictors of vancomycin trough level. Patients who received <10 mg/kg doses of vancomycin (N=18) achieved a median trough of 21.5 mcg/mL, with 83% being therapuetic. In patients who received >10 mg/kg (N=142), the median trough was 25.5 mcg/mL, with 47% being therapeutic. Conclusion and Relevance: Vancomycin dose, dialysate rate, UOP, and weight are independently associated with vancomycin trough concentration. In CVVHD patients, vancomycin dosed at 10 mg/kg every 24 hours may be an appropriate recommendation.
Sex‐related differences in the trends and outcomes of trans‐septal transcatheter mitral valve replacement: Insights from the National Readmissions Database
Elbadawi, Ayman , Tan, Bryan E‐Xin , Saad, Marwan , Sharaf, Barry L., Gordon, Paul , Saad, Marwan , Tan, Bryan E-Xin , Sammour, Yasser M. , Omer, Mohamed , Baron, Suzanne J. , Abbott, J. Dawn

Mayo Clinic

Catheterization and Cardiovascular Interventions | February 8, 2022 | Volume: 99 | Issue: 5 | Pages: 1636-1644

10.1002/ccd.30072 | PMID 35132765 Get It

AbstractBackgroundThere is a paucity of data regarding the sex‐related differences in the trends and outcomes of trans‐septal transcatheter mitral valve replacement (TS‐TMVR).MethodsThe Nationwide Readmissions Database (2015–2018) was queried for admissions for TS‐TMVR. Propensity matched analysis was conducted to compare outcomes with hospitalizations for TS‐TMVR among women versus men. The main study outcome was in‐hospital mortality.ResultsOur final analysis included 2063 hospitalizations for TS‐TMVR; of whom, 58.1% were women. The proportion of women among those undergoing TS‐TMVR increased from 50% in 2015 to 60.2% in 2018 (Ptrend = 0.04). Compared with men, women undergoing TS‐TMVR were slightly younger, and had a distinct profile of comorbidities. After matching, there was no significant difference in in‐hospital mortality among women versus men undergoing TS‐TMVR (7.8% vs. 6.1%, OR = 1.30; 95% CI: 0.79–2.13). Subgroup analyzes showed an interaction toward higher mortality with women versus men among patients with CKD (Pinteraction = 0.07). There were no significant differences between women and men in in‐hospital complications or length of stay after TS‐TMVR. Compared with men, women undergoing TS‐TMVR were more likely to be discharged to a nursing facility (17.7% vs. 11.5%, p = 0.01) and had higher rates of 30‐day readmissions (22.4% vs. 13.6%, p = 0.01).ConclusionThis nationwide analysis showed an increase in the proportion of women among patients undergoing TS‐TMVR during the study years. There were no differences in in‐hospital mortality, in‐hospital complications, or length of stay between both sexes following TS‐TMVR. Women were more likely to be discharged to nursing facilities and had higher rates of readmission at 30 days even after propensity matching.
Does Proximal Hamate Graft for Proximal Scaphoid Reconstruction Restore Native Wrist Kinematics?
Burnier, Marion , Gil, Joseph A. , Hooke, Alexander W. , Elhassan, Bassem T. , Kakar, Sanjeev , Hooke, Alexander, Elhassan, Bassem, Kakar, Sanjeev , Elhassan, Bassem T.

Mayo Clinic

HAND | February 8, 2022 | Volume: 18 | Issue: 5 | Pages: 732-739

10.1177/15589447211063570 | PMID 35130742 Get It

Background: The objective of this study was to determine whether reconstruction of the proximal pole of the scaphoid with a proximal hamate graft restores native carpal kinematics. Methods: A cadaveric study was designed assessing wrist kinematic after proximal hamate graft for proximal pole of the scaphoid nonunion. Wireless sensors were mounted to the carpus using a custom pin and suture anchor system to 8 cadavers. A wrist simulator was used to move the wrist through a cyclical motion about the flexion/extension and radial/ulnar deviation axes. Each specimen was tested under a series of 3 conditions: (1) a native state, “Intact”; (2) fractured scaphoid proximal pole, “Fracture”; and (3) post-reconstruction of the proximal pole of the scaphoid using a proximal hamate graft, “Graft.” Results: The fracture condition resulted in a statistically significant change in scapholunate kinematics across the entire arc of motion relative to the intact condition. Reconstruction with proximal hamate grafts restored scapholunate kinematics close to the intact state in both flexion/extension and radial/ulnar deviation axes. The lunocapitate flexion during wrist flexion was significantly different after the hamate graft reconstruction. Conclusions: Proximal hamate to scaphoid transfer resulted in restoration of near normal carpal kinematics to the intact state.